[eGongsi Notice] KOSDAQ - 2 Days

[Asia Economy Reporter Ji Yeon-jin]

◆ AIBIT = KOSDAQ Market Headquarters decided to delist AIBIT; suspension of trading of shares to be lifted from June 4

◆ S&C Engine Group = KOSDAQ Market Headquarters requested a disclosure inquiry regarding the truth and specific details of reports on the sale of major subsidiaries

◆ Ecomister = KOSDAQ Market Headquarters received an objection to the delisting of Ecomister and granted an improvement period

◆ Samco = KOSDAQ Market Headquarters to resume the Corporate Evaluation Committee review to decide on Samco’s delisting

◆ Joeun Saramdeul = Filed for commencement of rehabilitation proceedings at the court

◆ Magic Micro = KOSDAQ Market Headquarters issued a preliminary notice designating as an unfaithful disclosure corporation

◆ Jaan Bio = Merger by absorption with Maehong L&F

◆ Inowise = Filed for injunction to suspend the effect of delisting decision

KOSDAQ Market Headquarters suspends trading of shares until the court’s decision on the injunction to suspend the effect of delisting decision is confirmed

◆ Gaon Media = Decided to issue convertible bonds worth 10.5 billion KRW to raise operating funds

◆ Sambo Industry = Response to KOSDAQ Market Headquarters disclosure inquiry: "No relation to whether Lee Jun-seok, former Supreme Council member of the People Power Party’s father is the court-appointed manager of Hydrogen Power (currently Sambo Auto)"

◆ Medicox = Decided to issue convertible bonds worth 20 billion KRW to acquire securities of other companies and for other funds

◆ Chorokbaem Company = Acquired new shares of affiliate Chorokbaem Media worth 20 billion KRW through third-party allotment paid-in capital increase

◆ Yushin = Decided to lend 16 billion KRW to subsidiary Cheongsin Leisure

◆ AD Chips = Decided on a paid-in capital increase worth 24.4 billion KRW through general public offering of forfeited shares after shareholder allotment

◆ Samchundang Pharmaceutical = Regarding reports on attracting 200 billion KRW investment for oral insulin, "After signing a strategic alliance with a Chinese partner for oral insulin and oral GLP-1, we are continuously discussing business-related matters (after delivering the draft Term Sheet on May 10, including detailed contents and clinical schedules)"